Proprietary Cell Technology

 

CET develops disease and patient-specific induced pluripotent stem (iPS) cells and progenitor cells for the preclinical markets. Along with its partnership with the John Paul II Medical Research Institute (JP2MRI), CET has develop proprietary technology in iPS cell reprogramming from a variety of patients with clinical diseases and among patients from a wide-range of ages. Prior technology to create iPS cells is largely very inefficient and tedious and iPS transformation is quite random. CET has created novel technologies that increases cellular programming efficiency and decreases the time and cost to create iPS cell colonies from a variety of target cells and from patients of a wide range of ages with diseases that are even resistant to conventional iPS cell reprogramming.

 

CET has also developed proprietary technology to isolate personalized human cells from skin and human airways using minimally-invasive approaches. Current commercial human airway cells are derived from discarded lungs rejected for transplantation or are derived from human cadavers. The tissue and cellular phenotype can not be controlled from these tissue sources and, thus, are not personalized. CET has developed scalable human cells from routine diagnostic and minimally-invasive procedures.